File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Liver cancer working group report

TitleLiver cancer working group report
Authors
KeywordsDiagnosis
Epidemiology
Etiology
Liver cancer
Treatment
Issue Date2010
PublisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
Citation
Japanese Journal Of Clinical Oncology, 2010, v. 40 SUPPL. 1, p. i19-i27 How to Cite?
AbstractHepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation. © The Author (2010). Published by Oxford University Press. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/129387
ISSN
2015 Impact Factor: 1.889
2015 SCImago Journal Rankings: 0.847
ISI Accession Number ID
Funding AgencyGrant Number
Bristol-Myers Squibb
Pfizer Inc.
Bayer Healthcare
Bukwang Pharmaceutical Co.
Funding Information:

The author, Joong-Won Park, participated in phase II and phase III clinical studies sponsored by Bristol-Myers Squibb, Pfizer Inc., Bayer Healthcare and Bukwang Pharmaceutical Co. He is also a member of BMS Brivanib study steering committee, Pfizer Sunitinib advisory committee, and Bukwang Pharmacetutical Co. advisory committee.

References

 

DC FieldValueLanguage
dc.contributor.authorKudo, Men_HK
dc.contributor.authorHan, KHen_HK
dc.contributor.authorKokudo, Nen_HK
dc.contributor.authorCheng, ALen_HK
dc.contributor.authorChoi, BIen_HK
dc.contributor.authorFuruse, Jen_HK
dc.contributor.authorIzumi, Nen_HK
dc.contributor.authorPark, JWen_HK
dc.contributor.authorPoon, RTen_HK
dc.contributor.authorSakamoto, Men_HK
dc.date.accessioned2010-12-23T08:36:37Z-
dc.date.available2010-12-23T08:36:37Z-
dc.date.issued2010en_HK
dc.identifier.citationJapanese Journal Of Clinical Oncology, 2010, v. 40 SUPPL. 1, p. i19-i27en_HK
dc.identifier.issn0368-2811en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129387-
dc.description.abstractHepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation. © The Author (2010). Published by Oxford University Press. All rights reserved.en_HK
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/en_HK
dc.relation.ispartofJapanese Journal of Clinical Oncologyen_HK
dc.subjectDiagnosisen_HK
dc.subjectEpidemiologyen_HK
dc.subjectEtiologyen_HK
dc.subjectLiver canceren_HK
dc.subjectTreatmenten_HK
dc.titleLiver cancer working group reporten_HK
dc.typeArticleen_HK
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/jjco/hyq123en_HK
dc.identifier.pmid20870915-
dc.identifier.scopuseid_2-s2.0-77957268387en_HK
dc.identifier.hkuros183296en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77957268387&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume40en_HK
dc.identifier.issueSUPPL. 1en_HK
dc.identifier.spagei19en_HK
dc.identifier.epagei27en_HK
dc.identifier.isiWOS:000282175200004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridKudo, M=7203018682en_HK
dc.identifier.scopusauthoridHan, KH=7402963689en_HK
dc.identifier.scopusauthoridKokudo, N=35394468400en_HK
dc.identifier.scopusauthoridCheng, AL=54790561500en_HK
dc.identifier.scopusauthoridChoi, BI=7402755373en_HK
dc.identifier.scopusauthoridFuruse, J=35403873500en_HK
dc.identifier.scopusauthoridIzumi, N=7102192003en_HK
dc.identifier.scopusauthoridPark, JW=34974558100en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.scopusauthoridSakamoto, M=7402113400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats